RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
The Salt Difference Personalized, Holistic Care : We dont believe in one-size-fits-all solutions
Clinicians should also stay updated on emerging data
CRP-mediated inflammation in atherosclerosis during SARS-CoV-2 infection may be related to the presence of mCRP in the lesions (188, 198, 204, 263, 267269)
In preclinical and clinical research, it has been investigated for its effects on glycemic control, body weight, and cardiometabolic risk factors in obesity and type 2 diabetes models
Deep learning in estimating prevalence and systemic risk factors for diabetic retinopathy: a multi-ethnic study